50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.
BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet System
Royal Biologics' Cryo-Cord™, Amnio-Maxx™, Amnio-Maxx™ Lite and Derm-Maxx™ Receive High-Tier Reimbursement in the Hospital Outpatient Departments and Reimbursement in the Physician Office to Treat Chronic Non-Healing Wounds
The acquisition of the FIBRINET system adds new novel technology to Royal Biologics' growing portfolio of Autologous Live Cell solutions
Maxx-Cell has created a new gold standard in bone marrow aspiration therapy.